The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Alpha Before Beta: Exceptional Response to First-Line 225Ac-DOTATATE in a Patient of Metastatic Neuroendocrine Tumor With Extensive Skeletal Involvement.
Abstract
Abstract The utility of β-emitter 177Lu-DOTATATE in patients of neuroendocrine tumors (NETs) with widespread skeletal metastases is limited by its relatively modest response rates and a significant concern for hematotoxicity. In such situations, targeted α therapy with 225Ac-DOTATATE can be potentially beneficial. In this report, a 46-year-old man with rectal NET and extensive skeletal metastases was treated upfront with 6 cycles of 225Ac-DOTATATE at 8 weeks’ intervals. The patient showed excellent symptomatic, biochemical, and radiological response with no grade 3/4 adverse events. The first-line use of 225Ac-DOTATATE, therefore, presents a novel strategy for metastatic NETs with high skeletal disease burden.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a rectal NET case report, using 225Ac-DOTATATE as first-line treatment presents a novel strategy for metastatic NETs with high skeletal disease burden.
“Using 225Ac-DOTATATE as first-line treatment presents a novel strategy for metastatic NETs with high skeletal disease burden.”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [164]
Citations
Cites
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Chan, D. L. H., Pavlakis, N., Schembri, G. P., Bernard, E. J., Hsiao, E., Hayes, A. R., Barnes, T. A., Diakos, C. I., Khasraw, M., Samra, J. S., et al. (2017) · Theranostics · doi:10.7150/thno.18068 · Cited by 296
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215
Development of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 2
Poty, S., Francesconi, L. C., McDevitt, M. R., Morris, M. J., & Lewis, J. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.204651 · Cited by 114
Radiobiological effects of the alpha emitter Ra-223 on tumor cells
Bannik, K., Madas, B. G., Jarzombek, M., Sutter, A. P., Siemeister, G., Mumberg, D., & Zitzmann-Kolbe, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-54884-7 · Cited by 51
Zhang, J., Kulkarni, H., & Baum, R. P. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002915 · Cited by 41
Satapathy, S., Mittal, B. R., Sood, A. K., et al. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003170 · Cited by 28
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
Metadata
- Authors
- Satapathy, S., Sood, A., Das, C. K., Kavanal, A. J., & Mittal, B. R.
- Affiliations
- Nuclear Medicine
- Post Graduate Institute of Medical Education and Research (IN)
- Corresponding author
- Satapathy, Swayamjeet
- Sood, Ashwani
- Venue
- Clinical Nuclear Medicine
- Published
- 2021-07-20
- Volume
- 47
- Issue
- 2
- Pages
- e156-e157
- ISSN
- 0363-9762 (ISSN-L)
- 1536-0229
- OpenAlex
- W4288058787
- Cited by
- 14
- References
- 8
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 1
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Nuclear Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 177Lu-DOTATATE, neuroendocrine tumors, rectal neuroendocrine tumors, bone metastasis, targeted alpha therapy, first-line therapy, hematologic toxicity, radionuclide therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
